Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 19, 2023 - Issue 3
Submit an article Journal homepage
2,820
Views
1
CrossRef citations to date
0
Altmetric
HPV

Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine

Neerja Bhatlaa Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, New Delhi, IndiaView further author information
,
Richard Muwongeb Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, FranceView further author information
,
Sylla G. Malvic Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Solapur, IndiaView further author information
,
Smita Joshid Jehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, IndiaView further author information
,
Usha Rani Reddy Polie Public Health Foundation of India, IIPH-H, Hyderabad, IndiaView further author information
,
Eric Lucasb Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, FranceView further author information
,
Pulikkottil O. Esmyf Department of Oncology, Christian Fellowship Community Health Centre, Ambillikai (near Oddanchathram), IndiaView further author information
,
Yogesh Vermag Sikkim Manipal Institute of Medical Sciences, Sikkim Manipal University, Gangtok, IndiaView further author information
,
Anand Shahh Gujarat Cancer & Research Institute (GCRI), M.P. Shah Cancer Hospital, Civil Hospital Campus, Ahmedabad, IndiaView further author information
,
Eric Zomawiai National Health Mission, Civil Hospital, Aizawl, IndiaView further author information
,
Sharmila Pimplej Department of Preventive Oncology, Centre for Cancer Epidemiology (CCE), Homi Bhabha National Institute, Tata Memorial Centre, Mumbai, IndiaView further author information
,
Kasturi Jayantc Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Solapur, IndiaView further author information
,
Sanjay Hingmirec Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Solapur, IndiaView further author information
,
Aruna Chiwatec Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Solapur, IndiaView further author information
,
Shachi Vashista Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, New Delhi, IndiaView further author information
,
Gauravi Mishraj Department of Preventive Oncology, Centre for Cancer Epidemiology (CCE), Homi Bhabha National Institute, Tata Memorial Centre, Mumbai, IndiaView further author information
,
Radhika Jadhavd Jehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, IndiaView further author information
,
Maqsood Siddiqik Cancer Foundation of India, Kolkata, IndiaView further author information
,
Devasena Anantharamanl Cancer Research Division, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, IndiaView further author information
,
Gitika Panickerm National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USAView further author information
,
Julia Buttn Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, GermanyView further author information
,
Subha Sankaranl Cancer Research Division, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, IndiaView further author information
,
Thiraviam Pillai Rameshwari Ammal Kannanl Cancer Research Division, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, IndiaView further author information
,
Rintu Varghesel Cancer Research Division, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, IndiaView further author information
,
Purnima Karthal Cancer Research Division, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, IndiaView further author information
,
M. Radhakrishna Pillail Cancer Research Division, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, IndiaView further author information
,
Tim Waterboern Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, GermanyView further author information
,
Martin Müllern Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, GermanyView further author information
,
Peter Sehro EMBL-DKFZ Chemical Biology Core Facility, European Molecular Biology Laboratory, Heidelberg, GermanyView further author information
,
Elizabeth R. Ungerm National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USAView further author information
,
Rengaswamy Sankaranarayananp Kerala Operations, Karkinos Healthcare, Ernakulam, IndiaView further author information
&
Partha Basub Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0124-4050View further author information
ORCID Icon show all
Article: 2289242 | Received 02 Oct 2023, Accepted 25 Nov 2023, Published online: 11 Dec 2023

References

  • World Health Organization. Human papillomavirus vaccines: WHO position paper (2022 update). Wkly Epidemiol Rec. 2022;97(50):645–10. https://apps.who.int/iris/handle/10665/365350.
  • Man I, Georges D, de Carvalho TM, Ray Saraswati L, Bhandari P, Kataria I, Siddiqui M, Muwonge R, Lucas E, Berkhof J, et al. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study. Lancet Oncol. 2022 Nov;23(11):1419–1429. doi:10.1016/S1470-2045(22)00543-5.
  • Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S1–10. doi:10.1016/j.ygyno.2008.05.036.
  • Stanley M. HPV - immune response to infection and vaccination. Infect Agent Cancer. 2010 Oct 20;5(1):19. doi:10.1186/1750-9378-5-19.
  • Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev. 2010 Jul;236(1):125–38. doi:10.1111/j.1600-065X.2010.00912.x.
  • Khodadadi L, Cheng Q, Radbruch A, Hiepe F. The maintenance of memory plasma cells. Front Immunol. 2019 Apr 5;10:721. doi:10.3389/fimmu.2019.00721.
  • Single-Dose HPV Vaccine Evaluation Consortium. Review of the current published evidence on single-dose HPV vaccination. 4th Edition. 2022 [accessed 2023 Aug 8]. 20220328_SDHPV_Evidence_Review_Edition_4_Final_L2.pdf(path.org).
  • Kreimer AR, Sampson JN, Porras C, Schiller JT, Kemp T, Herrero R, Wagner S, Boland J, Schussler J, Lowy DR, et al. Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial. J Natl Cancer Inst. 2020 Oct 1;112(10):1038–46. doi:10.1093/jnci/djaa011.
  • Joshi S, Anantharaman D, Muwonge R, Bhatla N, Panicker G, Butt J, Rani Reddy Poli U, Malvi SG, Esmy PO, Lucas E, et al. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. Vaccine. 2023 Jan 4;41(1):236–45. doi:10.1016/j.vaccine.2022.11.044.
  • Bhatla N, Nene BM, Joshi S, Esmy PO, Poli URR, Joshi G, Verma Y, Zomawia E, Pimple S, Prabhu PR, et al. Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in India. Papilloma Res. 2018 Jun;5:163–171. doi:10.1016/j.pvr.2018.03.008.
  • Panicker G, Rajbhandari I, Pathak HN, Brady AM, Unger ER. Multiplex immunoassay to measure antibody response to nine HPV vaccine types. J Immunol Methods. 2021 Nov;498:113136. doi:10.1016/j.jim.2021.113136.
  • WHO. Human papillomavirus laboratory manual, 1st ed., 2009. World Health Organization; 2010. https://www.who.int/immunization/hpv/learn/hpv_laboratory_manual__who_ivb_2009_2010.pdf:.
  • World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;92(19):241–268. https://iris.who.int/handle/10665/255354.
  • Nygård M, Saah A, Munk C, Tryggvadottir L, Enerly E, Hortlund M, Sigurdardottir LG, Vuocolo S, Kjaer SK, Dillner J. Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine. Clin Vaccine Immunol. 2015 Aug;22(8):943–8. doi:10.1128/CVI.00133-15.
  • Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018 Apr;18(4):240–54. doi:10.1038/nrc.2018.13.
  • Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci USA. 2009 Dec 1; 106(48):20458–63. doi:10.1073/pnas.0908502106.
  • Basu P, Carvalho AL, Almonte M, Chajès V, Weiderpass E. Pulling the investment levers on implementation research in oncology. Lancet Oncol. 2022 Apr;23(4):451–2. doi:10.1016/S1470-2045(22)00025-0.
  • Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol. 2011 Dec;85(24):13253–9. doi:10.1128/JVI.06093-11.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.